Dr. Annah Sharp Rolig, PhD, is a Staff Scientist at the Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Sciences University. She holds a PhD in Cell, Developmental, and Molecular Biology from the University of California, Santa Cruz, and completed postdoctoral training in focusing on host-microbe interactions at the University of Oregon. Dr. Rolig's career spans over 15 years, including key roles at the Earle A. Chiles Research Institute. Her research has focused on immune interfaces, beginning with the study of pathogenic and commensal bacteria and evolving into translational cancer immunotherapy. Leveraging expertise in flow cytometry, multiplex immunohistochemistry, and RNA sequencing, Dr. Rolig has advanced our understanding of tumor immunology and developed novel combination therapies to enhance anti-tumor immunity. Her impactful work on in cancer immunotherapy and host-microbe interactions has been published in Science Translational Medicine, eLife, and Cell Host & Microbe. Currently, Dr. Rolig focuses on translational cancer biology, with a particular interest in developing novel therapeutic drugs to improve patient outcomes.